<DOC>
	<DOCNO>NCT00865579</DOCNO>
	<brief_summary>Parkinson 's Disease ( PD ) major neurodegenerative disorder progressive loss dopamine-containing neuron . The understanding PD syndrome dopamine ( DA ) deficiency lead introduction clinical practice L-dopa , precursor DA cross blood brain barrier , also use selective inhibitor MAO-B , major DA metabolising enzyme human . Safinamide inhibitor MAO-B . This study evaluate long term safety tolerability safinamide PD patient , already complete previous clinical study Safinamide . The physical neurological condition well safety parameter get compare baseline subsequent visit .</brief_summary>
	<brief_title>Open-Label Trial Determine Long-Term Safety Safinamide Parkinson 's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>1. subject complete previous clinical study Safinamide PD 2. subject successfully complete trial requirement antecedent trial 3. female , must either postmenopausal least 2 year , surgically sterilize undergone hysterectomy , child bear potential , must willing avoid pregnancy use adequate method contraception four week prior , four week last dose study medication . For purpose trial woman child bear potential define female subject puberty unless postmenopausal least two year , surgically sterile sexually inactive 4. subject must willing able participate trial provide write informed consent 1. subject experience clinically significant adverse effect attributable Investigational Medicinal Product ( IMP ) previous trial could put subject risk treatment Safinamide 2. female , subject pregnant lactate 3. medical issue , emerge since initial clinical trial , opinion investigator precludes subject 's ability participate openlabel trial</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>MAO inhibitor</keyword>
	<keyword>motor fluctuation</keyword>
	<keyword>dyskinesia</keyword>
	<keyword>Parkinson 's Disease</keyword>
</DOC>